Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

This study compares giving brain radiation therapy early versus later in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that has spread to a small number of areas in the brain. All patients will receive a targeted drug called almonertinib. **You may be eligible if...** - You have been diagnosed with NSCLC confirmed by biopsy - Your tumor has an EGFR mutation (specifically exon 19 deletion or L858R) - You have fewer than 5 brain metastases visible on MRI, with the tumors at least 3mm from the optic nerve and brainstem - You have not previously received any treatment for your brain metastases or any EGFR-targeting drugs **You may NOT be eligible if...** - You have already been treated for brain metastases - You have already received EGFR-targeted therapy (such as osimertinib or erlotinib) - You have more than 4 brain tumors Talk to your doctor to see if this trial is right for you.